IL317103A - Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof - Google Patents
Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereofInfo
- Publication number
- IL317103A IL317103A IL317103A IL31710324A IL317103A IL 317103 A IL317103 A IL 317103A IL 317103 A IL317103 A IL 317103A IL 31710324 A IL31710324 A IL 31710324A IL 317103 A IL317103 A IL 317103A
- Authority
- IL
- Israel
- Prior art keywords
- bcl
- met
- methods
- drug conjugates
- inhibitor antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263344460P | 2022-05-20 | 2022-05-20 | |
| PCT/US2023/022959 WO2023225336A1 (en) | 2022-05-20 | 2023-05-19 | Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL317103A true IL317103A (en) | 2025-01-01 |
Family
ID=86861809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL317103A IL317103A (en) | 2022-05-20 | 2023-05-19 | Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250339547A1 (en) |
| EP (1) | EP4525926A1 (en) |
| JP (1) | JP2025517429A (en) |
| KR (1) | KR20250027282A (en) |
| CN (1) | CN119562832A (en) |
| AR (1) | AR129382A1 (en) |
| AU (1) | AU2023273734A1 (en) |
| CA (1) | CA3256012A1 (en) |
| IL (1) | IL317103A (en) |
| TW (1) | TW202404645A (en) |
| WO (1) | WO2023225336A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202617186A (en) * | 2024-06-28 | 2026-05-01 | 美商飛爾富來生物公司 | Bcl-xl degrader antibody conjugates and uses thereof |
| WO2026051926A1 (en) * | 2024-09-04 | 2026-03-12 | 成都科岭源医药技术有限公司 | Exatecan mesylate-based antibody-drug conjugate, preparation method therefor and use thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2779780A (en) | 1955-03-01 | 1957-01-29 | Du Pont | 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JP3614866B2 (en) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ,インコーポレイティド | Artificial antibody polypeptide |
| JP2002532415A (en) | 1998-12-16 | 2002-10-02 | ワーナー−ランバート・カンパニー | Treatment of arthritis with MEK inhibitors |
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| AU7349801A (en) | 2000-07-19 | 2002-01-30 | Warner Lambert Co | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| SG2013013339A (en) | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| CA2512000C (en) | 2002-12-26 | 2011-08-09 | Eisai Co., Ltd. | Selective estrogen receptor modulator |
| KR100883289B1 (en) | 2004-06-11 | 2009-02-11 | 니뽄 다바코 산교 가부시키가이샤 | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido [2,3-D] pyrimidine derivatives and related compounds for cancer treatment |
| TR201808537T4 (en) | 2004-09-23 | 2018-07-23 | Genentech Inc | Cysteine modified antibodies and conjugates. |
| JP4557003B2 (en) | 2005-07-01 | 2010-10-06 | 株式会社村田製作所 | MULTILAYER CERAMIC SUBSTRATE, MANUFACTURING METHOD THEREOF, AND COMPOSITE GREEN SHEET FOR PRODUCTION OF MULTILAYER CERAMIC SUBSTRATE |
| PE20110217A1 (en) | 2006-08-02 | 2011-04-01 | Novartis Ag | DERIVATIVES OF 2-OXO-ETHYL-AMINO-PROPIONAMIDE-PYRROLIDIN-2-IL-SUBSTITUTED AS INHIBITORS OF THE BINDING OF THE PROTEIN Smac TO THE INHIBITOR OF THE PROTEIN OF APOPTOSIS |
| CA2660546A1 (en) | 2006-08-21 | 2008-02-28 | Genentech, Inc. | Aza-benzofuranyl compounds and methods of use |
| TWI441820B (en) | 2007-12-19 | 2014-06-21 | Genentech Inc | 5-anilinoimidazopyridines and methods of use |
| AU2009284098B2 (en) | 2008-08-22 | 2012-03-29 | Astex Therapeutics Ltd. | Pyrrolopyrimidine compounds as CDK inhibitors |
| KR101685718B1 (en) | 2008-12-19 | 2016-12-12 | 제넨테크, 인크. | Heterocyclic compounds and methods of use |
| EP2376085B1 (en) | 2008-12-19 | 2014-02-26 | Genentech, Inc. | Compounds and methods of use |
| BRPI1015234A2 (en) | 2009-06-22 | 2018-02-20 | Medimmune Llc | fc regions designed for site specific conjugation. |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| EP3205648A1 (en) | 2010-06-10 | 2017-08-16 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| BR112014002353B1 (en) | 2011-08-01 | 2022-09-27 | Genentech, Inc | USES OF PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND KIT |
| TWI571466B (en) | 2011-10-14 | 2017-02-21 | 艾伯維有限公司 | Apoptosis-inducing agent for treating cancer and immune and autoimmune diseases |
| TWI561521B (en) | 2011-10-14 | 2016-12-11 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| FR2986002B1 (en) | 2012-01-24 | 2014-02-21 | Servier Lab | NOVEL INDOLIZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| US20140069822A1 (en) | 2012-09-10 | 2014-03-13 | Antec Leyden B.V. | Electrochemical reduction of disulfide bonds in proteinaceous substances and electrochemical cell for carrying out such reduction |
| EA201591465A1 (en) | 2013-02-08 | 2015-12-30 | АйАрЭм ЭлЭлСи | SPECIFIC PLOTS FOR MODIFICATION OF ANTIBODIES FOR OBTAINING IMMUNOCONJUGATES |
| NZ710385A (en) | 2013-02-19 | 2016-10-28 | Novartis Ag | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders |
| FR3008975A1 (en) | 2013-07-23 | 2015-01-30 | Servier Lab | NOVEL PYRROLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| DK3063143T3 (en) | 2013-11-01 | 2018-08-20 | Novartis Ag | Amino heteroaryl benzamides as kinase inhibitors |
| FR3015483B1 (en) | 2013-12-23 | 2016-01-01 | Servier Lab | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
| BR112016020065A2 (en) | 2014-03-12 | 2018-02-20 | Novartis Ag | specific sites to modify antibodies to make immunoconjugates |
| MA39740A (en) | 2014-03-13 | 2017-01-18 | Hoffmann La Roche | Methods and compositions for modulating estrogen receptor mutants |
| MX378108B (en) | 2014-09-16 | 2025-03-10 | Servier Lab | ANTI-MET ANTIBODIES AND COMPOSITIONS. |
| JP2018502839A (en) | 2014-12-09 | 2018-02-01 | アッヴィ・インコーポレイテッド | Bcl-xL inhibitory compound and antibody drug conjugate containing the same |
| EP3229844B1 (en) | 2014-12-09 | 2020-03-04 | AbbVie Inc. | Antibody drug conjugates with cell permeable bcl-xl inhibitors |
| RU2017123942A (en) | 2014-12-09 | 2019-01-11 | Эббви Инк. | BCL-XL INHIBITING COMPOUNDS WITH LOW CELL PERMEABILITY AND ANTIBODY MEDICINES CONJUGATES INCLUDING THEM |
| WO2020000307A1 (en) | 2018-06-28 | 2020-01-02 | 深圳市汇顶科技股份有限公司 | Radio-frequency power adjustment method, ble chip, ble device and electronic terminal |
| AR119494A1 (en) | 2019-07-29 | 2021-12-22 | Servier Lab | 6,7-DIHYDRO-5H-PYRIDO[2,3-c]PYRIDAZIN-8-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PROAPOPTOTIC AGENTS |
| AR119493A1 (en) | 2019-07-29 | 2021-12-22 | Servier Lab | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PROAPOPTOTIC AGENTS |
| WO2021058735A1 (en) * | 2019-09-26 | 2021-04-01 | Symphogen A/S | Cancer treatment with anti-met antibody compositions |
| CN116761635A (en) * | 2020-11-24 | 2023-09-15 | 诺华股份有限公司 | BCL-XL inhibitor antibody drug conjugates and methods of use |
-
2023
- 2023-05-19 CN CN202380054393.1A patent/CN119562832A/en active Pending
- 2023-05-19 EP EP23732268.0A patent/EP4525926A1/en active Pending
- 2023-05-19 AR ARP230101260A patent/AR129382A1/en unknown
- 2023-05-19 US US18/866,134 patent/US20250339547A1/en active Pending
- 2023-05-19 CA CA3256012A patent/CA3256012A1/en active Pending
- 2023-05-19 TW TW112118821A patent/TW202404645A/en unknown
- 2023-05-19 KR KR1020247041742A patent/KR20250027282A/en active Pending
- 2023-05-19 IL IL317103A patent/IL317103A/en unknown
- 2023-05-19 JP JP2024568840A patent/JP2025517429A/en active Pending
- 2023-05-19 WO PCT/US2023/022959 patent/WO2023225336A1/en not_active Ceased
- 2023-05-19 AU AU2023273734A patent/AU2023273734A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023273734A1 (en) | 2024-12-12 |
| EP4525926A1 (en) | 2025-03-26 |
| CN119562832A (en) | 2025-03-04 |
| WO2023225336A8 (en) | 2024-07-18 |
| KR20250027282A (en) | 2025-02-25 |
| JP2025517429A (en) | 2025-06-05 |
| US20250339547A1 (en) | 2025-11-06 |
| AR129382A1 (en) | 2024-08-21 |
| TW202404645A (en) | 2024-02-01 |
| CA3256012A1 (en) | 2023-11-23 |
| WO2023225336A1 (en) | 2023-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288117A (en) | Mcl-1 inhibitor antibody-drug conjugates and methods of use | |
| IL304168A (en) | B7h4-targeted antibody-drug conjugates and methods of use thereof | |
| AU2022205057A9 (en) | B7h4-targeted antibody-drug conjugates and methods of use thereof | |
| IL317101A (en) | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof | |
| IL320894A (en) | Ceacam5 antibody-drug conjugates and methods of use thereof | |
| IL319484A (en) | Antibody-drug conjugates targeting napi2b and methods of use | |
| IL314828A (en) | Antibody-drug conjugates and their uses | |
| IL316049A (en) | Pharmaceutical compositions of mosunetuzumab and methods of use | |
| IL315862A (en) | Angiotensinogen-modulating compositions and methods of use thereof | |
| IL325551A (en) | Compositions and methods of using pln-targeting antibody-oligonucleotide conjugates | |
| IL325816A (en) | Endoxifen compositions and methods for their use and synthesis | |
| IL319485A (en) | Antibody-drug conjugates targeting glypican-3 and methods of use | |
| IL316020A (en) | Eribulin-based antibody-drug conjugates and methods of use | |
| HK40123865A (en) | Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof | |
| IL317102A (en) | Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof | |
| HK40102834A (en) | Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof | |
| IL326527A (en) | Compound and antibody-drug conjugate containing it | |
| HK40130279A (en) | Panras inhibitor antibody-drug conjugates and methods of use thereof | |
| CA3284856A1 (en) | Panras inhibitor antibody-drug conjugates and methods of use thereof | |
| IL319205A (en) | Tissue factor antibody-drug conjugates and uses thereof | |
| HK40102835A (en) | Mcl-1 inhibitor antibody-drug conjugates and methods of use | |
| HK40072336A (en) | Mcl-1 inhibitor antibody-drug conjugates and methods of use | |
| HK40073143A (en) | Mcl-1 inhibitor antibody-drug conjugates and methods of use | |
| HK40108912A (en) | Antibody-drug conjugates and methods of use thereof | |
| HK40102881A (en) | B7h4-targeted antibody-drug conjugates and methods of use thereof |